Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the
most common causes of death in AIDS patients.
Amphotericin B (AmB) is the corner stone in CM treatment. The effect of AmB was
dose-dependent. Recent retrospective study indicated that longer duration rather than higher
dose of AmB is necessary to reduce the mortality of CM. We aimed to explore the efficacy and
safety of small dose but longer duration of AmB for the treatment of HIV-associated CM.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Treatments:
Amphotericin B Flucytosine Liposomal amphotericin B